Synchron pauses clinical trials of its brain implant due to performance issues.

What it means

Synchron, a brain-computer interface startup, has paused enrollment in clinical trials for its Stentrode implant because the device's cable—the lead connecting the implant to a chest unit—failed to perform as expected. The company says the pause was voluntary, not ordered by the FDA, and that no safety issues have been identified; it plans to upgrade the entire system before resuming.

Accuracy & sourcesGrounded

The claim originates from a Wired article, an established secondary source, but the piece does not cite a primary document such as an FDA filing or a company press release. The search results from Superpower Daily and Wired's own social media confirm the same details, lending consistency, but the absence of a directly quoted primary source means the reporting's solidity is moderate—reliable for the headline facts but not independently verifiable from the given material.

How new